XML 79 R67.htm IDEA: XBRL DOCUMENT v3.23.3
Segments of Business - Reportable operating segment (Details)
$ in Millions
1 Months Ended 3 Months Ended 6 Months Ended
Jul. 31, 2022
USD ($)
Sep. 30, 2023
USD ($)
segment
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
segment
Sep. 30, 2022
USD ($)
Segment revenues          
Total revenues   $ 77,215 $ 70,157 $ 151,698 $ 137,311
Segment operating profit (loss)          
Total operating profit (loss)   951 1,124 2,051 2,160
Subtotal   1,141 1,278 2,483 2,368
Corporate income (expenses), net   (164) 21 (368) (18)
Interest expense   (61) (55) (108) (100)
Income from continuing operations before income taxes   916 1,244 $ 2,007 2,250
Number of reportable segments | segment       4  
Accounts receivable, credit loss expense (reversal)   210   $ 210  
Proceeds from legal settlements   79   197  
Pre-tax credits related to LIFO accounting       (87) 36
Fair value adjustment gain   48   76  
Loss (gain) to remeasure disposal group to fair value       0 (35)
Restructuring costs, anticipated total charges   $ 28 30 80 53
United States          
Segment operating profit (loss)          
Number of reportable segments | segment   3      
Corporate          
Segment operating profit (loss)          
Restructuring costs, anticipated total charges   $ 6 10 46 19
Corporate | Held-for-sale | E.U. Businesses (Disposal Group)          
Segment operating profit (loss)          
Loss (gain) to remeasure disposal group to fair value     (166)   (272)
U.S. Pharmaceutical          
Segment revenues          
Total revenues   69,766 60,059 136,926 117,006
Segment operating profit (loss)          
Total operating profit (loss)   $ 593 896 1,420 1,592
U.S. Pharmaceutical | Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk          
Segment operating profit (loss)          
Revenue derived from services, percentage (approximately or less than)   1.00%      
U.S. Pharmaceutical | Operating Segments          
Segment operating profit (loss)          
Pre-tax credits related to LIFO accounting   $ (55) 23 (87) 36
Gain from sale of equity method investment   142   142  
Proceeds from sale of equity securities $ 179        
Restructuring costs, anticipated total charges   9 3 11 7
Prescription Technology Solutions          
Segment revenues          
Total revenues   1,140 1,018 2,384 2,084
Segment operating profit (loss)          
Total operating profit (loss)   $ 238 120 469 264
Prescription Technology Solutions | Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk          
Segment operating profit (loss)          
Revenue derived from services, percentage (approximately or less than)   40.00%      
Prescription Technology Solutions | Operating Segments          
Segment operating profit (loss)          
Restructuring costs, anticipated total charges   $ 3 7 5 14
Medical-Surgical Solutions          
Segment revenues          
Total revenues   2,834 2,843 5,445 5,435
Segment operating profit (loss)          
Total operating profit (loss)   $ 244 299 471 555
Medical-Surgical Solutions | Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk          
Segment operating profit (loss)          
Revenue derived from services, percentage (approximately or less than)   2.00%      
Medical-Surgical Solutions | Operating Segments          
Segment operating profit (loss)          
Restructuring costs, anticipated total charges   $ 4 1 6 2
International          
Segment revenues          
Total revenues   3,475 6,237 6,943 12,786
Segment operating profit (loss)          
Total operating profit (loss)   $ 66 (37) 123 (43)
International | Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk          
Segment operating profit (loss)          
Revenue derived from services, percentage (approximately or less than)   1.00%      
International | Operating Segments          
Segment operating profit (loss)          
Restructuring costs, anticipated total charges   $ 6 9 $ 12 11
International | Operating Segments | Held-for-sale | E.U. Businesses (Disposal Group)          
Segment operating profit (loss)          
Loss (gain) to remeasure disposal group to fair value     $ 143   $ 237